Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is developing novel precision oncology therapies based on their proprietary Trans-Arterial Micro-Perfusion (TAMP) platform, which aims to improve therapeutic outcomes for cancer patients while minimizing toxicities. Their lead drug candidate, RenovoGem, is in a Phase 3 registration trial for pancreatic cancer and has potential in other indications. The company is making progress in commercialization of its FDA-cleared RenovoCath medical device, and with the addition of several new active commercial cancer centers, strong revenue growth is expected in the coming years. Despite some risks, the current valuation of RenovoRx is attractive, with a potential for high rewards in the billion-dollar market.

Bears say

RenovoRx is a clinical-stage biopharmaceutical company that has made progress in its clinical drug development and RenovoCath commercialization. However, with a market potential of only ~billion dollars, and pancreatic cancer having a 5-year combined overall survival rate of 12%, it is uncertain if the TIGeR-PaC study will be successful in providing a significant improvement in overall survival. Additionally, the recent appointment of a new CFO suggests that the company may be facing financial challenges that could negatively impact its future performance.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.